Post di ITTBioMed

𝐓𝐡𝐞 𝐀𝐮𝐭𝐨𝐧𝐨𝐦𝐨𝐮𝐬 𝐑𝐞𝐠𝐢𝐨𝐧 𝐎𝐟 𝐅𝐫𝐢𝐮𝐥𝐢 𝐕𝐞𝐧𝐞𝐳𝐢𝐚 𝐆𝐢𝐮𝐥𝐢𝐚 𝐎𝐩𝐞𝐧𝐬 𝐀 €𝟓 𝐌𝐢𝐥𝐥𝐢𝐨𝐧 𝐂𝐚𝐥𝐥 𝐓𝐨 𝐒𝐮𝐩𝐩𝐨𝐫𝐭 𝐓𝐡𝐞 𝐌𝐨𝐝𝐞𝐫𝐧𝐢𝐳𝐚𝐭𝐢𝐨𝐧 𝐎𝐟 𝐓𝐞𝐬𝐭𝐢𝐧𝐠 𝐀𝐧𝐝 𝐄𝐱𝐩𝐞𝐫𝐢𝐦𝐞𝐧𝐭𝐚𝐥 𝐈𝐧𝐟𝐫𝐚𝐬𝐭𝐫𝐮𝐜𝐭𝐮𝐫𝐞𝐬 𝐈𝐧 𝐓𝐡𝐞 𝐋𝐢𝐟𝐞 𝐒𝐜𝐢𝐞𝐧𝐜𝐞𝐬 𝐒𝐞𝐜𝐭𝐨𝐫 At the Urban Center headquarters in Trieste, the Autonomous Region of Friuli Venezia Giulia presented a new call in the Life Sciences sector. With a total allocation of €5 million in non-repayable funds, the initiative aims to modernize testing and experimental infrastructures within the regional territory, through the creation of new infrastructures or the enhancement of existing ones. https://lnkd.in/e3KcMJhR Regione Autonoma Friuli Venezia Giulia #ITTBioMed #Innovation #LifeSciences #FriuliVeneziaGiulia #Research

𝐍𝐞𝐯𝐚 𝐒𝐠𝐫 𝐈𝐧𝐯𝐞𝐬𝐭𝐬 𝐈𝐧 𝐁𝐢𝐨𝟒𝐃𝐫𝐞𝐚𝐦𝐬 𝐓𝐨 𝐁𝐨𝐨𝐬𝐭 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧 𝐈𝐧 𝐋𝐢𝐟𝐞 𝐒𝐜𝐢𝐞𝐧𝐜𝐞𝐬 NEVA SGR, the venture capital arm of the Intesa Sanpaolo Group, has taken an equity stake in Bio4Dreams Spa, an Italian incubator specializing in innovative start-ups within the Life Sciences sector. This investment was made through Neva Sgr’s Fondo Sei – Sviluppo ecosistemi di innovazione fund. https://lnkd.in/gX55RB4J #ITTBioMed #innovation #lifesciences

innovation and technology transfer oggi ne ha parlato Alessandro Fermi Regione Lombardia In diretta: https://lnkd.in/dvnGpmut

𝐍𝐞𝐰 𝐇𝐨𝐫𝐢𝐳𝐨𝐧𝐬 𝐈𝐧 𝐓𝐲𝐩𝐞 𝟏 𝐃𝐢𝐚𝐛𝐞𝐭𝐞𝐬: 𝐅𝐃𝐀 𝐀𝐩𝐩𝐫𝐨𝐯𝐚𝐥 𝐎𝐟 𝐋𝐚𝐧𝐭𝐢𝐝𝐫𝐚 𝐀𝐧𝐝 𝐄𝐦𝐞𝐫𝐠𝐢𝐧𝐠 𝐓𝐡𝐞𝐫𝐚𝐩𝐢𝐞𝐬 The FDA has given the green light to Lantidra (donislecel), the inaugural treatment utilizing donor-derived pancreatic islet cells for type 1 diabetes (T1D). Created by CellTrans, it’s designed for adults with T1D who struggle to control their blood sugar with insulin. Islet cell transplants have been accessible in the US for more than two decades, but only as experimental therapies in clinical trials. The approval of Lantidra confirms allogeneic cells as a therapeutic option for those who can’t detect blood sugar drops and encounter challenges with insulin dosing. The full article is available in the link below and it is written by Miriana Braghin, Department of Pharmacological and Biomolecular Sciences “Rodolfo Paoletti”, University of Milan. https://lnkd.in/d3uA_YNj #ittbiomed #biology #FDA #allogeneicells #bloodsugar #diabetes #type1 #Lantidra #pancreaticisletcells #clinicaltrials

BionIT Labs Closes A €5.5 Million Investment Round With CDP Venture Capital SGR, RIF Srl, Sefea Impact Sgr, SIMEST Spa, And ENEA Tech e Biomedical 💥💥💥 🎯 Investment goal: to make the Adam’s Hand bionic prosthesis the premier product in the American prosthetic market and to expand BionIT Labs’ product range https://lnkd.in/dGNTphGm